drugset / Trial / NCT05756920
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase 1, FIH, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, PK and PD after SAD and MAD in healthy adult participants.
Timeline
- Start
- 2022-12-31
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABL301 | Unknown | — | Intravenous |
Indications
No indication recorded.